Novavax, Inc. (NASDAQ: NVAX) has provided updates regarding its late-stage coronavirus study. The company has disclosed that it is planning to commence Phase III Clinical trial in Mexico and the US in the coming week. NVAX has also arranged alternative clinical sites to use in case of need. Biotechnology firm has shared that it has closed the recruitment in Phase III trial in the UK and Phase 2b efficacy trial in South Africa.

Novavax Inc. is continuolsy endeavoring to fulfill the emergency needs of people around the globe. NVAX has revealed that 15,000 volunteers will participate in the pivotal Phase III trial and a total of 4,422 patients will be recruited in the Phase 2b trial in South Africa.